Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.42 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.31 |
| ▸ | FEN1 | P39748 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21632538 | 0.90 | DGAT1 (0.45) | DGAT1F2RL1ALOX5APFEN1 | |
| SCHEMBL14158745 | 0.88 | DGAT1 (0.42) | DGAT1F2RL1 | |
| SCHEMBL30457445 | 0.88 | DGAT1 (0.42) | DGAT1F2RL1 | |
| SCHEMBL20422628 | 0.86 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL29663834 | 0.86 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL15753342 | 0.85 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL20443784 | 0.84 | — | — | |
| SCHEMBL21678419 | 0.83 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL31070092 | 0.83 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL20422563 | 0.83 | DGAT1 (0.39) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113620956-B | Transforming growth factor receptor antagonist, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | DGAT1 2711/4885F2RL1 1308/4885ALOX5AP 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.